

Status: Currently Official on 17-Feb-2025  
 Official Date: Official as of 01-May-2020  
 Document Type: USP Monographs  
 DocId: GUID-1F51343B-F01F-412E-80AC-D31053185F85\_5\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M23370\\_05\\_01](https://doi.org/10.31003/USPNF_M23370_05_01)  
 DOI Ref: 72273

© 2025 USPC  
 Do not distribute

## Dexamethasone Acetate

$C_{24}H_{31}FO_6 \cdot H_2O$  452.51

Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-9-fluoro-11,17-dihydroxy-16-methyl-, (11 $\beta$ ,16 $\alpha$ )-monohydrate.

9-Fluoro-11 $\beta$ ,17,21-trihydroxy-16 $\alpha$ -methylpregna-1,4-diene-3,20-dione 21-acetate monohydrate CAS RN®: 55812-90-3.

Anhydrous 434.51 CAS RN®: 1177-87-3.

» Dexamethasone Acetate contains one molecule of water of hydration or is anhydrous. It contains not less than 97.0 percent and not more than 102.0 percent of  $C_{24}H_{31}FO_6$ , calculated on the dried basis.

**Packaging and storage**—Preserve in well-closed containers. Store at 25°, excursions permitted between 15° and 30°.

**Labeling**—Label it to indicate whether it is hydrous or anhydrous.

**USP REFERENCE STANDARDS (11)**—

[USP Dexamethasone Acetate RS](#)

**Identification**—

**Change to read:**

**A:** ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy: 197M](#) ▲ (CN 1-May-2020)

**Change to read:**

**B:** ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Ultraviolet-Visible Spectroscopy: 197U](#) ▲ (CN 1-May-2020)

*Solution:* 15 µg per mL.

*Medium:* methanol.

Absorptivities at 239 nm, calculated on the dried basis, do not differ by more than 3.0%.

**SPECIFIC ROTATION (781S):** between +82° and +88°.

*Test solution:* 10 mg per mL, in dioxane.

**LOSS ON DRYING (731)**—Dry it in vacuum at 105° for 3 hours: the hydrous form loses between 3.5% and 4.5%, and the anhydrous form not more than 0.4%, of its weight.

**RESIDUE ON IGNITION (281):** not more than 0.1%.

**Change to read:**

**Chromatographic purity**—

▲ *Formate* ▲ (ERR 1-May-2020) *buffer*—Dissolve 1.32 g of ammonium formate in 1 L of water, adjust with formic acid to a pH of 3.6, and mix.

*Mobile phase*—Prepare a filtered and degassed mixture of *Formate buffer* and acetonitrile (3:2). Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

*Test solution*—Transfer about 200 mg of Dexamethasone Acetate, accurately weighed, to a 100-mL volumetric flask, dissolve in and dilute with acetonitrile to volume, and mix. Transfer about 40 mL of this solution to a 100-mL volumetric flask, dilute with *Formate buffer* to volume, and mix.

*Chromatographic system* (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 25-cm column that contains packing L11. The flow rate is about 1 mL per minute. Chromatograph the *Test solution*, and record the peak responses as directed for *Procedure*: the column efficiency is not less than 5400 theoretical plates.

*Procedure*—Inject a volume (about 10 µL) of the *Test solution* into the chromatograph, record the chromatogram, and measure the peak responses. Calculate the percentage of each impurity in the portion of Dexamethasone Acetate taken by the formula:

$$100(r_i/r_s)$$

in which  $r_i$  is the peak response for each impurity; and  $r_s$  is the sum of the responses of all the peaks: not more than 1.0% of any individual impurity is found; and not more than 2.0% of total impurities is found.

**Assay**—

*Mobile phase*—Prepare a filtered and degassed mixture of water and acetonitrile (550:450). Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

*pH 6.0 Buffer solution*—Transfer 3 mL of 1 N sodium hydroxide, 138 mL of 0.5 N potassium chloride, and 50 mL of 0.5 M monobasic potassium phosphate to a 1-L volumetric flask, dilute with water to volume, and mix.

*Diluent*—Prepare a mixture of acetonitrile and *pH 6.0 Buffer solution* (1:1).

*Standard preparation*—Transfer about 25 mg of [USP Dexamethasone Acetate RS](#), accurately weighed, to a 250-mL volumetric flask. Add 100 mL of *Diluent*, and sonicate until a clear solution is obtained. Dilute with *Diluent* to volume, and mix.

*Assay preparation*—Transfer about 25 mg of Dexamethasone Acetate, accurately weighed, to a 250-mL volumetric flask. Add 100 mL of *Diluent*, and sonicate until a clear solution is obtained. Dilute with *Diluent* to volume, and mix.

*Chromatographic system* (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with a 254-nm detector and a 3.9-mm × 30-cm column containing 10-µm packing L1. The flow rate is about 2 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the capacity factor, *k'*, is not less than 2.0; the column efficiency is not less than 1500 theoretical plates; the tailing factor is not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%.

*Procedure*—Separately inject equal volumes (about 20 µL) of the *Standard preparation* (before and after injections of the *Assay preparation*) and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of C<sub>24</sub>H<sub>31</sub>FO<sub>6</sub> in the portion of Dexamethasone Acetate taken by the formula:

$$250C(r_u/r_s)$$

in which *C* is the concentration, in mg per mL, of [USP Dexamethasone Acetate RS](#) in the *Standard preparation*; and *r<sub>u</sub>* and *r<sub>s</sub>* are the peak responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
DEXAMETHASONE ACETATE	<a href="#">Documentary Standards Support</a>	SM52020 Small Molecules 5
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM52020 Small Molecules 5

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**  
Pharmacopeial Forum: Volume No. PF 29(5)

**Current DocID:** GUID-1F51343B-F01F-412E-80AC-D31053185F85\_5\_en-US  
**DOI:** <https://doi.org/10.31003/USPNF.M23370.05.01>  
**DOI ref:** [72273](#)